Faron Pharmaceuticals Oy (LON:FARN) Trading Down 11.6% – Should You Sell?

Faron Pharmaceuticals Oy (LON:FARN) traded down 11.6% during mid-day trading on Wednesday . The stock traded as low as GBX 46 and last traded at GBX 47.29. 264,198 shares traded hands during trading, an increase of 41% from the average session volume of 187,918 shares. The stock had previously closed at GBX 53.50.

Faron Pharmaceuticals Oy Price Performance

The company has a market cap of £54.42 million, a price-to-earnings ratio of -1.74 and a beta of 1.60. The company has a 50-day simple moving average of GBX 125.07 and a 200-day simple moving average of GBX 164.88. The company has a debt-to-equity ratio of -133.35, a quick ratio of 1.09 and a current ratio of 0.84.

Insider Buying and Selling

In other Faron Pharmaceuticals Oy news, insider Jurriaan Dekkers sold 4,000 shares of the firm’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of GBX 182, for a total transaction of £7,280. Company insiders own 3.94% of the company’s stock.

Faron Pharmaceuticals Oy Company Profile

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.